Details of Bacterial Vaccine
This bacterial vaccine card gives comprehensive information about each vaccine.
| Detailed Information | |
|---|---|
| ID | 1241 |
| Name of the vaccine | H56 |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | 18 to 60 years |
| Description of the vaccine | H56 fusion protein is formulated with IC31. |
| Name of the manufacturer | Aeras |
| Name of the manufacturing country | South Africa, Tanzania |
| Year of manufacture | 2024 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Two doses with a 56 days interval. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | IC31 |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (2 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03512249 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA |